Business
Mirum Pharmaceuticals’ LIVMARLI Receives FDA Approval for Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis
- FDA approval based on MARCH Phase 3 study with highly statistically significant
About this update from Mirum Pharmaceuticals, Inc.
[{"type":"text","content":"\n- FDA approval based on MARCH Phase 3 study with highly statistically significant (p","length":147,"tagName":"div"}]